Gencor to introduce new berberine ingredient and present new research at SupplySide Global

Gencor and its exclusive delivery systems technology partner, Pharmako Biotechnologies, have announced the debut of BioBerb, a cold-water dispersible berberine, at SupplySide Global, taking place in Las Vegas, NV from October 29-30. Gencor explains in a press release that berberine is recognized for its antioxidant and anti-inflammatory effects, interacting with key enzymes that are vital regulators of energy production, glucose metabolism and immune function. The ingredient has seen particular interest because of its ability to support healthy blood sugar, and in particular stimulate GLP-1. That said, the traditional Indian Barberry root, Berberis aristata, requires high doses of berberine to be effective, which can lead to tolerability issues and adverse events such as digestive discomfort, explains Gencor.

The company’s BioBerb ingredient employs LipiSperse dispersion technology from Pharmako, improving absorption and bioavailability. “BioBerb is not just another supplement; it’s a smarter, more advanced way to support your health. If you're serious about optimizing your energy, blood sugar, and overall metabolic function, BioBerb is a clear choice,” said George Kokkinis, CEO of Pharmako Biotechnologies, in a press release.

Gencor will also be revealing new data on its proprietary Oleoylethanolamide (OEA) ingredient, Trpti, demonstrating its influence on weight management through the gut microbiome and through its effect on GLP-1 secretion and inhibition of DPP-4. OEA is also combined with LipiSperse delivery technology to make it highly bioavailable. In addition to the new research on OEA, Gencor will also highly recently published data on Levagen+ and its ability to enhance physiological resilience in female students.

Other previous research on Levagen+ for women has found that it may help alleviate menstrual symptoms. A recently published study showed that after ingestion of Levagen+, recorded menstrual pain was decreased at 1, 1.5, and 2 hours afterwards, with a reduction of at least 25% by 2.5 hours, compared with placebo.

“At Gencor, innovation begins with science that genuinely impacts how people feel and perform," said John Quilter, CEO of Gencor. "With BioBerb, Trpti, and Levagen, we’re pushing the limits of what’s possible in natural metabolic and joint health support. These ingredients demonstrate our ongoing commitment to turning advanced clinical research into effective, accessible wellness solutions for today’s active consumers."

Gencor is also hosting an education session featuring researchers Dr. Amanda Rao from RDC Global and Dr. Daniele Piomelli, PharmD, PhD, MD (h.c.). Director of the University of California Center for the Study of Cannabis & Cannabinoid Research and Rhizotomos Consulting. The session will last 50 minutes, with Rao presenting the new research on BioBerb and Piomelli sharing bioavailability data on Trpti and its role in supporting metabolic health. That session will be on October 29, 2025 from 4-4:50PM at the product development theater, booth #8076, Bayside B, Level 1.